SPOTLIGHT: Gottlieb outlines FDA's pharmacogenomic plans
Dr. Scott Gottlieb, the FDA's deputy commissioner for medical and scientific affairs, talks to the Seattle Times about the agency's focus on pharmacogenomics, the development of new guidelines for proteomic data and the need for drug developers to follow through on plans for post-marketing studies. Report
Comments